© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - Biocon to go Ahead with Syngene IPO, Listing Likely in July
Posted 19th May 2015

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biotechnology major Biocon on Wednesday filed a prospectus with market regulator Securities and Exchange Board of India (Sebi) for the Initial Public Offer (IPO) of its research arm, Syngene, through which it aims to raise around Rs 600 crore for funding research and development (R&D).

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biocon to go Ahead with Syngene IPO, Listing Likely in July

View Biography
Amarchand & Mangaldas

Biopharmaceuticals major Biocon on Tuesday said that the unlocking of the value from its contract research subsidiary Syngene would help the company fund its research and development programmes.

Syngene has already filed the draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), seeking approval for an initial public offering (IPO). The company is estimated to be raising around Rs 600 crore through this public issue.

“We are unlocking value from Syngene to fund our R&D programmes, which include a rich pipeline of biosimilars and novel biologics. This fund infusion will help accelerate these programmes which are at various stages of development currently,” said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL), currently holds an 84.5 per cent equity stake in Syngene. The company is offering to sell up to 22 million equity shares of face value of Rs 10 each, through Syngene’s IPO.

The offer includes a reservation of two million equity shares for Biocon’s public equity shareholders, being individuals and Hindu Undivided Families (HUFs). The offer would constitute 11 per cent of the post offer paid-up equity share capital of the company.

Established in 1993, Syngene offers a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. The company’s service offerings also support the development of biosimilar and generic molecules.

During the nine months period-ended December 31, 2014, Syngene serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014.

Syngene had reported revenues of Rs 707.7 crore for the previous financial year-ended March 31, 2014 and Rs 617.5 crore for the nine months period ended December 31, 2014. Earlier this month, the company appointed Peter Bains as its Chief Executive Officer. Bains has been a part of Syngene since January 2010 as a director and has more than two decades of experience in the pharmaceutical space.

“Syngene has a proven track record of providing quality NME discovery, development and manufacturing services. It has long-standing partnerships with three of the world’s leading global healthcare organisations, including Bristol-Myers Squibb Co. and has attracted equity participation from India Value Fund recently, which is reflective of the scale, the value and the quality of the differentiated business model of Syngene,” added Mazumdar-Shaw.

Categories: Finance


You Might Also Like
Read Full PostRead - Eye Icon
Understanding Personal Injury Legal Services
News
27/05/2024Understanding Personal Injury Legal Services

When we hear the term “personal injury,” we often think of obvious physical wounds like broken bones, cuts, or bruises. However, personal injury cases encompass much more than just visible harm. Personal injury law recognizes that accidents and neg

Read Full PostRead - Eye Icon
Bridgepoint Developement Capital acquisition of stake in MVF
Finance
04/08/2015Bridgepoint Developement Capital acquisition of stake in MVF

Bridgepoint Developement Capital acquisition of stake in MVF

Read Full PostRead - Eye Icon
Avoiding the merger control blues
Legal
19/06/2018Avoiding the merger control blues

Effective handling of antitrust issues can help businesses bolster their negotiating position—whichever side of the deal they're on.

Read Full PostRead - Eye Icon
The Truth About “Guaranteed” Links in SaaS
News
21/07/2025The Truth About “Guaranteed” Links in SaaS

In the digital marketing sphere, links play a crucial role in enhancing a software-as-a-service (SaaS) company’s online presence. Many businesses are drawn to the promise of “guaranteed” links, hoping to boost their search engine rankings swi

Read Full PostRead - Eye Icon
Access Technology’s Acquisition of Changeworknow
M&A
21/05/2015Access Technology’s Acquisition of Changeworknow

Access Technology's Acquisition of Changeworknow

Read Full PostRead - Eye Icon
Why Data is and Always Will Be The Next Big Thing
Innovation
07/08/2020Why Data is and Always Will Be The Next Big Thing

Data has ushered in a new digital era for businesses, society and individuals – one that’s revolutionizing customer and employee experiences, creating more dynamic, responsive, and personalised business models, and even sparking entirely new industries.

Read Full PostRead - Eye Icon
Who Is the Best EDI Service?
News
25/04/2025Who Is the Best EDI Service?

Small businesses often need electronic data interchange (EDI) services to better communicate with their clients. For example, a B2B business might send and receive purchase orders and invoices. An EDI utilises a standard format and prompts the user to fill in

Read Full PostRead - Eye Icon
Why Client Trust, Not Volume, Should Drive Growth in Professional Services
Legal
08/10/2026Why Client Trust, Not Volume, Should Drive Growth in Professional Services

Almost every professional services firm eventually reaches the same fork in the road. One path optimises for volume: more leads, more clients, more matters moving through the pipeline. The other optimises for trust: fewer relationships, held to a higher standa

Read Full PostRead - Eye Icon
Solana: The Rising Star Paving the Way for Bitcoin’s Evolution
Finance
15/08/2023Solana: The Rising Star Paving the Way for Bitcoin’s Evolution

In the vast and dynamic realm of cryptocurrencies, one project has been gaining significant attention and acclaim: Solana. With its exceptional scalability and innovative features, Solana has emerged as a rising star in the crypto space.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow